These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12735908)

  • 1. Preface: Malignant syndrome in Parkinson's disease.
    Narabayashi H; Mizuno Y
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S1. PubMed ID: 12735908
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroleptic malignant syndrome in advanced Parkinson's disease.
    Gordon PH; Frucht SJ
    Mov Disord; 2001 Sep; 16(5):960-2. PubMed ID: 11746631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clozapine for drug-induced psychosis in Parkinson's disease.
    Brown TM
    N Engl J Med; 1999 Aug; 341(6):456. PubMed ID: 10438274
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.
    Clarke CE
    J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):510-1; author reply 511. PubMed ID: 14966183
    [No Abstract]   [Full Text] [Related]  

  • 5. Malignant syndrome in Parkinson's disease: concept and review of the literature.
    Mizuno Y; Takubo H; Mizuta E; Kuno S
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S3-9. PubMed ID: 12735909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic malignant syndrome in parkinsonian patients: risk factors.
    Kuno S; Mizuta E; Yamasaki S
    Eur Neurol; 1997; 38 Suppl 2():56-9. PubMed ID: 9387804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group.
    Ikebe S; Harada T; Hashimoto T; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Takubo H; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S47-9. PubMed ID: 12735915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication.
    Stotz M; Thümmler D; Schürch M; Renggli JC; Urwyler A; Pargger H
    Br J Anaesth; 2004 Dec; 93(6):868-71. PubMed ID: 15377584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic malignant-like syndrome: case report.
    Tibbels CK; Seegers S
    Tex Med; 1988 May; 84(5):40-3. PubMed ID: 3406898
    [No Abstract]   [Full Text] [Related]  

  • 11. A case of malignant syndrome associated with a parkinsonism patient.
    Sanga M; Nomura S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Apr; 23(2):91-5. PubMed ID: 12762221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
    Bonnici A; Ruiner CE; St-Laurent L; Hornstein D
    Ann Pharmacother; 2010 Sep; 44(9):1504-7. PubMed ID: 20628041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic malignant syndrome-like condition in multiple system atrophy.
    Konagaya M; Goto Y; Matsuoka Y; Konishi T; Konagaya Y
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):120-1. PubMed ID: 9221984
    [No Abstract]   [Full Text] [Related]  

  • 14. Neuroleptic malignant syndrome without neuroleptics.
    Parsa MA; Rohr T; Ramirez LF; Meltzer HY
    J Clin Psychopharmacol; 1990 Dec; 10(6):437-8. PubMed ID: 2286714
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroleptic malignant like syndrome in two patients on cholinesterase inhibitors.
    Grace JB; Thompson P
    Int J Geriatr Psychiatry; 2006 Feb; 21(2):193-4. PubMed ID: 16440373
    [No Abstract]   [Full Text] [Related]  

  • 16. A 77-year-old man with Parkinson's disease and hyperthermia.
    Madigan EJ
    J Emerg Nurs; 2008 Jun; 34(3):229-30. PubMed ID: 18558256
    [No Abstract]   [Full Text] [Related]  

  • 17. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease.
    Hashimoto T; Tokuda T; Hanyu N; Tabata K; Yanagisawa N
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S25-30. PubMed ID: 12735912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a chronically constipated parkinsonian patient.
    Shimada J; Sakakibara R; Uchiyama T; Liu Z; Yamamoto T; Ito T; Mori M; Asahina M; Hattori T
    Eur J Neurol; 2006 Mar; 13(3):306-7. PubMed ID: 16618352
    [No Abstract]   [Full Text] [Related]  

  • 19. [Neuroleptic malignant syndrome after withdrawal of levopoda].
    Cedeno-Veloz B; Areosa Sastre A
    Rev Esp Geriatr Gerontol; 2018; 53(5):299-300. PubMed ID: 29628214
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
    Ward C
    J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.